NZ586302A - Pre-surgical treatment using brimonidine applied topically to reduce bleeding or bruising - Google Patents

Pre-surgical treatment using brimonidine applied topically to reduce bleeding or bruising

Info

Publication number
NZ586302A
NZ586302A NZ586302A NZ58630208A NZ586302A NZ 586302 A NZ586302 A NZ 586302A NZ 586302 A NZ586302 A NZ 586302A NZ 58630208 A NZ58630208 A NZ 58630208A NZ 586302 A NZ586302 A NZ 586302A
Authority
NZ
New Zealand
Prior art keywords
bruising
brimonidine
surgical treatment
applied topically
reduce bleeding
Prior art date
Application number
NZ586302A
Other languages
English (en)
Inventor
Jack A Dejovin
Original Assignee
Galderma Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Lab Inc filed Critical Galderma Lab Inc
Publication of NZ586302A publication Critical patent/NZ586302A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
NZ586302A 2007-12-21 2008-12-17 Pre-surgical treatment using brimonidine applied topically to reduce bleeding or bruising NZ586302A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1591207P 2007-12-21 2007-12-21
PCT/US2008/013797 WO2009082452A1 (en) 2007-12-21 2008-12-17 Pre-surgical treatment

Publications (1)

Publication Number Publication Date
NZ586302A true NZ586302A (en) 2013-03-28

Family

ID=40801507

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ586302A NZ586302A (en) 2007-12-21 2008-12-17 Pre-surgical treatment using brimonidine applied topically to reduce bleeding or bruising

Country Status (10)

Country Link
US (1) US20110224215A1 (enExample)
EP (1) EP2230910A4 (enExample)
JP (1) JP5580210B2 (enExample)
KR (1) KR20100099191A (enExample)
CN (1) CN101902913B (enExample)
AU (1) AU2008341112B2 (enExample)
BR (1) BRPI0822095A2 (enExample)
CA (1) CA2709199A1 (enExample)
NZ (1) NZ586302A (enExample)
WO (1) WO2009082452A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
PT2818184T (pt) * 2007-11-16 2019-01-28 Aclaris Therapeutics Inc Composições e métodos para o tratamento de púrpura
US20120295914A1 (en) * 2009-05-29 2012-11-22 Galderma Research & Development Combination of adrenergic receptor agonist alpha-1 or alpha-2, preferably brimonidine with fillers, preferably hyaluronic acid
WO2011117378A2 (en) * 2010-03-26 2011-09-29 Galderma Research & Development Improved methods and compositions for safe and effective treatment of telangiectasia
CN103298472A (zh) 2010-03-26 2013-09-11 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物
FR2966366B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel de brimonidine
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
ES2498217T5 (es) * 2010-10-21 2018-03-19 Galderma S.A. Composición en forma de gel basada en brimonidina
RU2013123043A (ru) * 2010-10-21 2014-12-10 Галдерма С.А. Гелевая композиция для местного применения
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
WO2013057579A2 (en) 2011-10-19 2013-04-25 Galderma Pharma S.A. Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
JP6339364B2 (ja) * 2013-12-27 2018-06-06 カズマパートナーズ株式会社 無定形ブリモニジン酒石酸塩及びその製造方法
WO2019083771A1 (en) * 2017-10-23 2019-05-02 Microcures, Inc. METHOD FOR IMPROVING THE RECOVERY OF A SKIN TREATED WITH A COSMETIC LASER

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
CA2154979A1 (en) * 1995-07-28 1997-01-29 Kenneth T. Armstrong Topical phenylephrine preparation
US7973068B2 (en) * 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
PT2818184T (pt) * 2007-11-16 2019-01-28 Aclaris Therapeutics Inc Composições e métodos para o tratamento de púrpura

Also Published As

Publication number Publication date
US20110224215A1 (en) 2011-09-15
WO2009082452A1 (en) 2009-07-02
CN101902913B (zh) 2014-06-18
JP5580210B2 (ja) 2014-08-27
AU2008341112B2 (en) 2014-02-06
EP2230910A1 (en) 2010-09-29
EP2230910A4 (en) 2011-04-13
CA2709199A1 (en) 2009-07-02
AU2008341112A1 (en) 2009-07-02
BRPI0822095A2 (pt) 2014-10-07
CN101902913A (zh) 2010-12-01
KR20100099191A (ko) 2010-09-10
JP2011507845A (ja) 2011-03-10

Similar Documents

Publication Publication Date Title
AU2012204164A8 (en) Melanin modification compositions and methods of use
WO2012050831A3 (en) Combination treatment for dermatological conditions
IL213359A0 (en) Use of a foamable composition essentially free of pharmaceutically active ingredients for the treatment of human skin
NZ714963A (en) Compositions and methods for treating anemia
WO2008070859A3 (en) Treatment of skin conditions by dickkopf1 (dkk1)
NZ576424A (en) Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
WO2012047645A3 (en) Combination treatment for rosacea
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
MX348531B (es) Dispositivo de lata de aerosol para suministro tópico dual.
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
NZ594184A (en) Skin treatment
NZ599265A (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
TW200602030A (en) Use of loteprednol etabonate for the treatment of dry eye
WO2007102090A3 (en) Topical formulation
TW200719882A (en) Treatment of connective tissue diseases of the skin
WO2010151778A3 (en) Topical compositions and methods for wound care
EA201590546A1 (ru) Способы лечения заболеваний, связанных с волосами
RU2011148355A (ru) Применение аллопуринола для ладонно-родошвенного синдрома
WO2014049561A3 (en) Oral composition for reinforcing skin tolerance following topical administration of a retinoid compound
WO2014182610A3 (en) Alpha adrenergic agonists for in the treatment of tissue trauma
WO2007105071A3 (en) Composition for cosmetic or pharmaceutical-dermatological use
TN2011000366A1 (en) Use of deferiprone for treatment and prevention of iron-related eye dosorders
WO2008088987B1 (en) Treatment of pain with naloxone
WO2007144889A3 (en) Treatment of neurofibromatosis

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 DEC 2015 BY AJ PARK

Effective date: 20131023

LAPS Patent lapsed